SpectraCure AB (publ)

Stockholm Stock Exchange SPEC.ST

SpectraCure AB (publ) Capital Expenditure for the year ending December 31, 2023: USD -1.56 M

SpectraCure AB (publ) Capital Expenditure is USD -1.56 M for the year ending December 31, 2023, a -61.07% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

SpectraCure AB (publ) Capital Expenditure for the year ending December 31, 2022 was USD -966.17 K, a -3.34% change year over year.
SpectraCure AB (publ) Capital Expenditure for the year ending December 31, 2021 was USD -934.97 K, a 27.11% change year over year.
SpectraCure AB (publ) Capital Expenditure for the year ending December 31, 2020 was USD -1.28 M, a 20.32% change year over year.
SpectraCure AB (publ) Capital Expenditure for the year ending December 31, 2019 was USD -1.61 M, a -52.34% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Stockholm Stock Exchange: SPEC.ST

SpectraCure AB (publ)

CEO	Dr. Masoud Khayyami Ph.D.
IPO Date	July 1, 2015
Location	Sweden
Headquarters	Gasverksgatan 1
Employees	13
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clinical trial for the treatment of solid tumors. The company was founded in 2003 and is based in Lund, Sweden.

Key trends

Past 5 years